Patents Represented by Attorney, Agent or Law Firm Mary M. Krinsky
  • Patent number: 6037468
    Abstract: Tertiary alcohols containing the structural features illustrated in 3 or 4 below (Scheme I) are prepared by reacting at least one diazo carbonyl compound, e.g., 1 in Scheme I) and at least one allylic alcohol (e.g., 2 in Scheme I) in a coupling reaction run under conditions that produce carbene or carbenoid intemediates from the diazo containing substrate such as transition metal catalysis or either thermal or photochemical decomposition. In some preferred embodiments, Rh.sub.2 (OAc).sub.4 is employed to catalyze the coupling reaction. ##STR1## Indolocarbazoles (e.g., 7 below) are prepared by coupling of diazo carbonyl compounds (e.g., 5) and biindoles (e.g., 6). Indolocarbazoles are furanosylated (e.g., 7) with acetals (e.g., 8) or their open chain congeners (e.g., 9) under conditions known to promote acetal exchange or formation, such as protic or Lewis acids. Furanosylated indolocarbazoles (e.g., 10) are also prepared via ring contraction of pyranosylated indolocarbazoles (e.g.
    Type: Grant
    Filed: December 4, 1998
    Date of Patent: March 14, 2000
    Assignee: Yale University
    Inventors: John L. Wood, Brian M. Stoltz
  • Patent number: 6004970
    Abstract: Nicotine dependency is treated by administration of an opioid antagonist. In some embodiments, rapid or ultra rapid detoxification techniques include using a combination of an effective amount of an opioid antagonist such as nalmefene, naloxone or naltrexone or a mixture of any one of these, and either clonidine or related compounds either while awake, or while under sedation or anesthesia, followed by continued administration of an effective amount of an opioid antagonist with or without agents that enhance nicotine dependency treatment.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: December 21, 1999
    Assignee: Yale University
    Inventors: Stephanie O'Malley, Boris Meandzija, Suchitra Krishnan-Sarin, Patrick G. O'Connor
  • Patent number: 5525496
    Abstract: A gene encoding Saccharomyces cerevisiae sterol .DELTA.14 reductase of the ergosterol biosynthetic pathway is isolated and cloned by selecting strains carrying sequences on a 2.mu. based vector for resistance to a morpholine fungicide such as fenpropimorph. Four distinct plasmid inserts which produce morpholine resistance are obtained, and one of these is characterized and sequenced. The purified and isolated DNA sequence encoding sterol .DELTA.14 reductase encodes a polypeptide exhibiting homology to the S. cerevisiae sterol C-24(28) reductase enzyme in the ergosterol biosynthetic pathway.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: June 11, 1996
    Assignee: American Cyanamid Company
    Inventors: Margaret Hsien-fen Kuh Lai, Donald R. Kirsch, Martin Bard
  • Patent number: 5512472
    Abstract: A gene encoding Saccharomyces cerevisiae sterol .DELTA.14 reductase of the ergosterol biosynthetic pathway is isolated and cloned by selecting strains carrying sequences on a 2.mu. based vector for resistance to a morpholine fungicide such as fenpropimorph. Four distinct plasmid inserts which produce morpholine resistance are obtained, and one of these is characterized and sequenced. The purified and isolated DNA sequence encoding sterol .DELTA.14 reductase encodes a polypeptide exhibiting homology to the S. cerevisiae sterol C-24(28) reductase enzyme in the ergosterol biosynthetic pathway.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 30, 1996
    Assignee: American Cyanamid Company
    Inventors: Margaret H. K. Lai, Donald R. Kirsch, Martin Bard
  • Patent number: 5418144
    Abstract: A method for the identification of agents which inhibit spindle pole body formation or function, thus exhibiting selective fungicidal activity, involves the incubation of test samples in cultures of a Saccharomyces cerevisiae strain that produces excess numbers of spindle pole bodies. Cultures containing samples that inhibit spindle pole bodies exhibit enhanced growth because the growing yeast is rescued from the adverse effects of excess spindle bodies. In the preferred practice of the invention, the test sample is added to a S. cerevisiae culture or culture area containing a strain that has a conditional mutation producing excess spindle pole bodies, such as diploid esp1-1 strains. The culture or culture area is preincubated under permissive conditions wherein the strain can grow to some extent, and then conditions are shifted to restrictive conditions so that the mutant strain either cannot grow or grows poorly.
    Type: Grant
    Filed: May 25, 1993
    Date of Patent: May 23, 1995
    Assignee: American Cyanamid Company
    Inventors: Donald R. Kirsch, Margaret H. K. Lai